Compugen (NASDAQ: CGEN) was upgraded by Zacks Investment Research on Monday, August 6 from a "sell" rating to a "hold" rating in an explanation to investors.
According to Zacks, "Compugen Ltd. is a pioneer in the field of computational genomics and proteomics." The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Computing in these areas is used to develop core technologies and platforms that form the basis for its products and services, and these products and services are designed to enable life scientists to significantly improve their research efforts in the field of drug discovery. "
Apart from this, ValuEngine has put Compugen from a "hold" assessment into a "sell" assessment in a study letter on Friday, May 11th.
Shares of CGEN declined during the afternoon trade on Monday by $ 0.15 to $ 3.90. 178,000 shares of the company were traded, compared with the average volume of 241,662. The stock has a market capitalization of $ 192.35 million, a PE ratio of -5.42 and a beta of 0.27. Compugen has a 1-year low of $ 2.25 and a 1-year high of $ 5.00.
Compugen (NASDAQ: CGEN) has published its quarterly results for the last time on Wednesday, August 1st. The biotechnology company reported ($ 0.19) EPS for the quarter and reached the Zacks consensus estimate of ($ 0.19). analysts predict that Compugen will be available for the current year after -0.45 EPS.
Several large investors have recently added or reduced their stake in CGEN. ARK Investment Management LLC increased its equity stake in Compugen by 34.5% in the second quarter. ARK Investment Management LLC now owns 5,372,874 shares of the biotechnology company's business worth $ 17,730,000 after acquiring additional 1,379,123 shares in the last quarter. UBS Group AG increased its stake in Compugen by 1,813.2% during the first quarter. UBS Group AG now owns 316,066 shares in the share capital of the biotechnology company with a value of $ 1,406,000 after the purchase of another 299,546 shares in the last quarter. Taylor Frigon Capital Management LLC increased the interest in Compugen in the second quarter by 24.3%. Taylor Frigon Capital Management LLC now holds 666,302 shares of the biotechnology company's stock valued at $ 2,199,000 after buying 130,217 additional shares in the last quarter. Jane Street Group LLC acquired a new stake in Compugen in the fourth quarter, worth about $ 192,000. Finally, Renaissance Technologies LLC increased its stake in Compugen by 26.5% in the fourth quarter. Renaissance Technologies LLC now owns 340,008 shares of the biotechnology company's stock valued at $ 850,000 after buying an additional 71,308 shares in the last quarter. Institutional investors and hedge funds hold 20.77% of the company's shares.
Compugen Company profile
Compugen Ltd., a therapeutic discovery company, is engaged in the research, development and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncological programs against new drug targets in the field of unmet medical needs in different cancer types and patient populations.
Read more: short selling shares, a beginner's guide
Receive a free copy of the Zack research report on Compugen (CGEN)
Visit Zacks.com for more information about research offers from Zacks Investment Research
Receive news and valuations for Compugen Daily – Enter your email address below to receive a concise, daily summary of the latest news and analyst ratings for Compugen and related companies with the FREE daily email newsletter from MarketBeat.com.
Source link